These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

77 related items for PubMed ID: 11076110

  • 41. Renagel: reducing serum phosphorus in haemodialysis patients.
    Burke SK.
    Hosp Med; 2000 Sep; 61(9):622-7. PubMed ID: 11048603
    [Abstract] [Full Text] [Related]

  • 42. Determination of the binding parameter constants of Renagel capsules and tablets utilizing the Langmuir approximation at various pH by ion chromatography.
    Swearingen RA, Chen X, Petersen JS, Riley KS, Wang D, Zhorov E.
    J Pharm Biomed Anal; 2002 Jun 20; 29(1-2):195-201. PubMed ID: 12062678
    [Abstract] [Full Text] [Related]

  • 43. A phosphate binding assay for sevelamer hydrochloride by ion chromatography.
    Mazzeo JR, Peters RM, Hanus MR, Chen X, Norton KA.
    J Pharm Biomed Anal; 1999 May 20; 19(6):911-5. PubMed ID: 10698557
    [Abstract] [Full Text] [Related]

  • 44. Molecular modeling studies of the binding characteristics of phosphates to sevelamer hydrochloride--assessing a novel technique to reduce phosphates contamination.
    Parker R, Odukale AA, Fisher D, Batich C, Ross E, Edwards J.
    Int J Environ Res Public Health; 2006 Jun 20; 3(2):202-8. PubMed ID: 16823094
    [Abstract] [Full Text] [Related]

  • 45. Trends in the incidence of intestinal perforation in US dialysis patients (1992-2005).
    Yang JY, Lee TC, Montez-Rath ME, Desai M, Winkelmayer WC.
    J Nephrol; 2013 Jun 20; 26(2):281-8. PubMed ID: 22419235
    [Abstract] [Full Text] [Related]

  • 46. The influence of poly(allylamine hydrochloride) hydrogel crosslinking density on its thermal and phosphate binding properties.
    Elsiddig R, O'Reilly NJ, Hudson SP, Owens E, Hughes H, O'Grady D, McLoughlin P.
    Int J Pharm; 2022 Jun 10; 621():121806. PubMed ID: 35526696
    [Abstract] [Full Text] [Related]

  • 47. Transient decrease of serum bicarbonate levels with Sevelamer hydrochloride as the phosphate binder.
    Gallieni M, Cozzolino M, Brancaccio D.
    Kidney Int; 2000 Apr 10; 57(4):1776-7. PubMed ID: 10809607
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Accuracy of interqual criteria in determining the hospitalization need in medicare patients with gastrointestinal bleeding.
    Irvin CB, Nigl J, Lowe RA.
    Acad Emerg Med; 2000 Oct 10; 7(10):1166. PubMed ID: 11015257
    [Abstract] [Full Text] [Related]

  • 52. [This is how patients can feel].
    Tijdschr Ziekenverpl; 1976 Feb 17; 29(4):171. PubMed ID: 1045668
    [No Abstract] [Full Text] [Related]

  • 53. Impact of prescription benefit coverage limits on sevelamer hydrochloride adherence for patients with ESRD.
    Bhardwaja B, Carroll N, Korner E, Nair KV.
    Am Health Drug Benefits; 2009 Sep 17; 2(6):242-50. PubMed ID: 25126297
    [Abstract] [Full Text] [Related]

  • 54. Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study.
    Ruggeri M, Bellasi A, Cipriani F, Molony D, Bell C, Russo D, Di Iorio B.
    J Nephrol; 2015 Oct 17; 28(5):593-602. PubMed ID: 25027030
    [Abstract] [Full Text] [Related]

  • 55. Sevelamer carbonate: a review in hyperphosphataemia in adults with chronic kidney disease.
    Perry CM, Plosker GL.
    Drugs; 2014 May 17; 74(7):771-92. PubMed ID: 24811546
    [Abstract] [Full Text] [Related]

  • 56. Sevelamer as a phosphate binder in adult hemodialysis patients: an evidence-based review of its therapeutic value.
    Nadin C.
    Core Evid; 2005 May 17; 1(1):43-63. PubMed ID: 22496676
    [Abstract] [Full Text] [Related]

  • 57. Hospitalization risks between Renagel phosphate binder treated and non-Renagel treated patients.
    Collins AJ, St Peter WL, Dalleska FW, Ebben JP, Ma JZ.
    Clin Nephrol; 2000 Oct 17; 54(4):334-41. PubMed ID: 11076110
    [Abstract] [Full Text] [Related]

  • 58. Sevelamer hydrochloride use and circulating endotoxin in hemodialysis patients: a pilot cross-sectional study.
    Sun PP, Perianayagam MC, Jaber BL.
    J Ren Nutr; 2009 Sep 17; 19(5):432-8. PubMed ID: 19464926
    [Abstract] [Full Text] [Related]

  • 59. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.
    Shaheen FA, Akeel NM, Badawi LS, Souqiyyeh MZ.
    Saudi Med J; 2004 Jun 17; 25(6):785-91. PubMed ID: 15195212
    [Abstract] [Full Text] [Related]

  • 60. Sevelamer worsens metabolic acidosis in hemodialysis patients.
    De Santo NG, Frangiosa A, Anastasio P, Marino A, Correale G, Perna A, Di Stazio E, Stellato D, Santoro D, Di Meglio E, Iacono G, Ciacci C, Savica V, Cirillo M.
    J Nephrol; 2006 Jun 17; 19 Suppl 9():S108-14. PubMed ID: 16736432
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.